跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
I-BRD9
首页
药物
I-BRD9
I-BRD9
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Use of I-BRD9 or derivatives thereof in preparing anti-epileptic drugs
US 11304935 B2
申请人: UNIV SOUTH CHINA
优先权: 2018
CN
US
2 件公开
INDOLIZINE COMPOUND AND USE THEREOF
WO 2026145825 A1
申请人: GUANGZHOU INST BIOMED & HEALTH
优先权: 2025
CN
WO
2 件公开
Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US 11285218 B2
申请人: DANA FARBER CANCER INST INC
优先权: 2017
US
BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE
US 2022315578 A1
申请人: NOVARTIS AG
优先权: 2020
US
Polycyclic derivative as well as composition and pharmaceutical application thereof
CN 115894479 A
申请人: HAISCO PHARMACEUTICAL GROUP CO LTD
优先权: 2021
CN
Compound for inhibiting or degrading BRD9 as well as composition and pharmaceutical application thereof
CN 118339151 A
申请人: TIBET HAISCO PHARMACEUTICAL CO LTD
优先权: 2021
CN
Nitrogen-containing heteroaromatic ring compound as well as composition and pharmaceutical application thereof
CN 118647616 A
申请人: TIBET HAISCO PHARMACEUTICAL CO LTD
优先权: 2022
CN
Fused heterocyclic compound as well as composition and pharmaceutical application thereof
CN 117050058 A
申请人: SICHUAN HAISCO PHARMACEUTICAL CO LTD
优先权: 2022
CN
BRD9在慢性淋巴细胞白血病诊治中的应用
CN 115261469 B
申请人: 山东第一医科大学附属省立医院(山东省立医院)
优先权: 2022
CN
I-BRD9作为ARIH1激动剂的用途
CN 115300507 B
申请人: 杭州天玑济世生物科技有限公司
优先权: 2022
CN
第 1 / 2 页
上一页
下一页
药物
反馈